The safety and efficacy of PDE5-inhibitors-vardenafil on treating diabetes mellitus erectile dysfunction

作者：Jia He, Li Xiao, Hengheng Dai, Jisheng Wang, Haisong Li, Xiaojun Zhang, Ping Wang, Dong Zhang, Lingyan Zuo, Ning Xie, Ying Li · 发表于：Medicine · 年份：2019 · DOI：10.1097/md.0000000000018361 · 被引用次数：7 · 研究领域：Sexual function and dysfunction studies、Phosphodiesterase function and regulation、Pharmaceutical Quality and Counterfeiting

BACKGROUND: Diabetic mellitus erectile dysfunction (DMED) refers to erectile dysfunction (ED) secondary to diabetes. As people's lifestyle changes and the population ages, the incidence of DMED continues to increase. Many clinical trials have proven that PDE5-inhibitors-vardenafil has a significant effect in the treatment of Diabetic mellitus erectile dysfunction. In this systematic review, we aim to evaluate the effectiveness and safety of PDE5-inhibitors-vardenafil for Diabetic mellitus erectile dysfunction. METHODS: We will search PubMed, Cochrane Library, AMED, EMbase, WorldSciNet; Nature, Science online and China Journal Full-text Database (CNKI), China Biomedical Literature CD-ROM Database (CBM), and related randomized controlled trials included in the China Resources Database. The time is limited from the construction of the library to February 2019.We will use the criteria provided by Cochrane 5.1.0 for quality assessment and risk assessment of the included studies, and use the Revman 5.3 and Stata13.0 software for meta-analysis of the effectiveness, recurrence rate, and symptom scores of Diabetic mellitus erectile dysfunction. ETHICS AND DISSEMINATION: This systematic review will evaluate the efficacy and safety of PDE5-inhibitors-vardenafil for treating Diabetic mellitus erectile dysfunction. Because all of the data used in this systematic review and meta-analysis has been published, this review does not require ethical approval. Furthermore, all data will be analyz...